HRMY241115C30000
- 4.80
- +0.90+23.08%
Harmony Biosciences Newsroom
Results: Harmony Biosciences Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Reported Earlier, Harmony Biosciences Shareholders Sell 8M Shares at $31 Each in Public Offering
Harmony Biosciences: JPMorgan Is Sole Manager for Offering >HRMY
Harmony Biosciences Expects Offering to Close Nov. 1 >HRMY
Harmony Biosciences Isn't Offering Any Shares in Offering, Won't Receive Any Proceeds From Sale of Shares >HRMY
Harmony Biosciences: Selling Shareholders Grant Underwriter Option for Additional 1.2M Shares >HRMY
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Harmony Biosciences Is Maintained at Overweight by Cantor Fitzgerald
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Maintains Target Price $28
Cantor Fitzgerald Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $58
Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $59
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Express News | Harmony Biosciences Holdings : Oppenheimer Raises Target Price to $59 From $56
Axonis Therapeutics Announces $115 Million Series A Financing
Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript Summary
Harmony Biosciences Up Over 14%, on Track for Highest Close Since March 2023 -- Data Talk
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
Harmony Biosciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results.
Analyst Expectations For Harmony Biosciences's Future